Glycated Hbg Index and RDW as Prognstic Indicator in Critical Ill Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Hbg and RDW.
- Who it may be relevant to
- Registry conditions: Critical Ill Patients. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Glycatetd Hemoglobin Index and Red Cell Distribution Width as Prognstic Indicator in Critical Ill Patients
Overview
The aim of this study was to evaluate the impact of GHI and RDW as prognostic indicator in critically ill Patients.
Detailed description
Primary (Main): determine the levels of the GHI And RDW In Critically Ill Patients at Critical and intermediate care units.
b. Secondary (Subsidiary): Evaluate the prognostic significance of these parameters on patient outcomes, such as overall survival, progression-free survival, response to treatment.
Interventions
- Device Hbg and RDW
Hbg and RDW as prognstic indicator in critical ill patients
Primary outcome measures
- Glycated Hemoglobin level [Time frame: Baseline]
- Red Cell Distribution Width (RDW) [Time frame: baseline]
- Hemoglobin (Hb) Level [Time frame: baseline]
Eligibility criteria
Inclusion criteria
- patients admitted to Critical and Intermediate Care Units in Internal Medicine Department after history taking, examination and diagnosis
- diabtic Patients 3-animic Patients
Exclusion criteria
- Patients under 18 years of age
- ICU stay < 24 h
- patients without HbA1c, FBG, or RDW data or anything's that's affect the HbA1c .
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07057154 · Rule of HBGA1C in critical ill